An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

Abroad (travel likely)RecruitingPHASE2

Conditions

Treatment Resistant Depression

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MAC Clinical Research, Liverpool, United Kingdom
Study coordinator · info@researchforyou.co.uk · 0800 917 7637
Hammersmith Medicines Research, London, United Kingdom
Study coordinator · REC@hmrlondon.com · +44 (0)20 8961 4130
King's College London, Clinical Trials Facility, London, United Kingdom

Study leads

Kevin Craig, M.D.
Study Director
Beckley Psytech Ltd

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Major Depressive Disorder · Suicide · Treatment Resistant Depression

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Treatment Resistant Depression · Chronic Pain

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

OSU6162 as add-on in SSRI/SNRI-resistant Depression

Depression · Depressive Disorder, Treatment-Resistant · Depressive Disorder

Abroad (travel likely)RecruitingPHASE2

Lund, Sweden · Gothenburg, Sweden

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Treatment Resistant Depression

Abroad (travel likely)RecruitingPHASE2

Ghent, Belgium